Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
ESMO Open
|
April 10, 2021
Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer
F Schettini, P Barbao, F Brasó-Maristany, et al.
ESMO Open
|
September 6, 2025
HER2DX ERBB2 score in advanced HER2-positive gastric cancer treated with trastuzumab and chemotherapy
D Pesántez, F Brasó-Maristany, T Pascual, et al.
ESMO Open
|
July 7, 2026
Molecular effects of ovarian stimulation for fertility preservation in breast cancer: a paired-biopsy analysis
Y Barral El Gaoui, F Brasó-Maristany, A Borrás Capó, et al.
ESMO Open
|
April 19, 2023
Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis
F Schettini, O Martínez-Sáez, C Falato, et al.
ESMO Open
|
March 5, 2024
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B)
G Villacampa, T Pascual, F Brasó-Maristany, et al.
ESMO Open
|
October 1, 2025
Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer
S Morganti, R J Kusmick, M E Hughes, et al.
ESMO Open
|
October 17, 2025
Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapy
R Gómez-Bravo, B Walbaum, M Bergamino, et al.
ESMO Open
|
January 18, 2025
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers
F Lynce, O Martínez-Sáez, B Walbaum, et al.
ESMO Open
|
November 28, 2024
Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study
F Schettini, F Brasó-Maristany, T Pascual, et al.
ESMO Open
|
April 10, 2025
Prevalence and clinical impact of germline pathogenic variants in breast cancer: a descriptive large single-center study
A Rodriguez-Hernandez, O Martínez-Sáez, F Brasó-Maristany, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
ESMO Open
|
April 10, 2021
Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer
F Schettini, P Barbao, F Brasó-Maristany, et al.
ESMO Open
|
September 6, 2025
HER2DX ERBB2 score in advanced HER2-positive gastric cancer treated with trastuzumab and chemotherapy
D Pesántez, F Brasó-Maristany, T Pascual, et al.
ESMO Open
|
July 7, 2026
Molecular effects of ovarian stimulation for fertility preservation in breast cancer: a paired-biopsy analysis
Y Barral El Gaoui, F Brasó-Maristany, A Borrás Capó, et al.
ESMO Open
|
April 19, 2023
Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis
F Schettini, O Martínez-Sáez, C Falato, et al.
ESMO Open
|
March 5, 2024
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B)
G Villacampa, T Pascual, F Brasó-Maristany, et al.
ESMO Open
|
October 1, 2025
Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer
S Morganti, R J Kusmick, M E Hughes, et al.
ESMO Open
|
October 17, 2025
Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapy
R Gómez-Bravo, B Walbaum, M Bergamino, et al.
ESMO Open
|
January 18, 2025
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers
F Lynce, O Martínez-Sáez, B Walbaum, et al.
ESMO Open
|
November 28, 2024
Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study
F Schettini, F Brasó-Maristany, T Pascual, et al.
ESMO Open
|
April 10, 2025
Prevalence and clinical impact of germline pathogenic variants in breast cancer: a descriptive large single-center study
A Rodriguez-Hernandez, O Martínez-Sáez, F Brasó-Maristany, et al.
Page
of 2